Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunological monitoring for guidance of preemptive antiviral therapy for active cytomegalovirus infection in allogeneic stem-cell transplant recipients: a pilot experience.

× No keyword cloud information.

11 in total

1. The kinetics of torque teno virus plasma DNA load shortly after engraftment predicts the risk of high-level CMV DNAemia in allogeneic hematopoietic stem cell transplant recipients.

Authors: E Albert; C Solano; E Giménez; D Focosi; A Pérez; L Macera; J L Piñana; J C H Boluda; F Maggi; D Navarro
Journal: Bone Marrow Transplant Date: 2017-10-30 Impact factor: 5.483

Review 2. Haploidentical hematopoietic transplantation without T-cell depletion: current status and future perspectives.

Authors: Lei Gao; Xi Zhang
Journal: Stem Cell Investig Date: 2015-10-20

3. Performance of the QuantiFERON-cytomegalovirus (CMV) assay for detection and estimation of the magnitude and functionality of the CMV-specific gamma interferon-producing CD8(+) T-cell response in allogeneic stem cell transplant recipients.

Authors: María Ángeles Clari; Beatriz Muñoz-Cobo; Carlos Solano; Isabel Benet; Elisa Costa; María José Remigia; Dayana Bravo; Paula Amat; David Navarro
Journal: Clin Vaccine Immunol Date: 2012-02-29

Review 4. Immune Monitoring for CMV in Transplantation.

Authors: Michelle K Yong; Sharon R Lewin; Oriol Manuel
Journal: Curr Infect Dis Rep Date: 2018-03-14 Impact factor: 3.725

Review 5. Improving cytomegalovirus-specific T cell reconstitution after haploidentical stem cell transplantation.

Authors: Xiao-Hua Luo; Ying-Jun Chang; Xiao-Jun Huang
Journal: J Immunol Res Date: 2014-04-24 Impact factor: 4.818

6. Efficacy and Safety of a Preemptive Antiviral Therapy Strategy Based on Combined Virological and Immunological Monitoring for Active Cytomegalovirus Infection in Allogeneic Stem Cell Transplant Recipients.

Authors: David Navarro; Paula Amat; Rafael de la Cámara; Javier López; Lourdes Vázquez; David Serrano; José Nieto; Monserrat Rovira; José Luis Piñana; Estela Giménez; Carlos Solano
Journal: Open Forum Infect Dis Date: 2016-05-18 Impact factor: 3.835

7. Evaluation of T-activated proteins as recall antigens to monitor Epstein-Barr virus and human cytomegalovirus-specific T cells in a clinical trial setting.

Authors: Nina Körber; Uta Behrends; Ulrike Protzer; Tanja Bauer
Journal: J Transl Med Date: 2020-06-17 Impact factor: 5.531

8. Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.

Authors: Euri Seo; Eun Seok Choi; Jung Hwa Kim; Hyery Kim; Kyung-Nam Koh; Ho Joon Im; Jina Lee
Journal: PLoS One Date: 2021-02-05 Impact factor: 3.240

9. Association of CMV-Specific T Cell-Mediated Immunity with CMV DNAemia and Development of CMV Disease in HIV-1-Infected Individuals.

Authors: Maximilian C Aichelburg; Lukas Weseslindtner; Mattias Mandorfer; Robert Strassl; Armin Rieger; Thomas Reiberger; Elisabeth Puchhammer-Stöckl; Katharina Grabmeier-Pfistershammer
Journal: PLoS One Date: 2015-08-31 Impact factor: 3.240

10. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications.

Authors: Siok-Keen Tey; Glen A Kennedy; Deborah Cromer; Miles P Davenport; Susan Walker; Linda I Jones; Tania Crough; Simon T Durrant; James A Morton; Jason P Butler; Ashish K Misra; Geoffrey R Hill; Rajiv Khanna
Journal: PLoS One Date: 2013-10-11 Impact factor: 3.240